Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)

Market Cap	1.86T +49.7%
Revenue (ttm)	157.23B +32.8%
Net Income	21.81B +8.9%
EPS	62.51 +5.7%
Shares Out	n/a
PE Ratio	85.23
Forward PE	67.43
Dividend	38.00 (0.78%)
Ex-Dividend Date	May 29, 2026

Volume	317,532
Open	4,885.00
Previous Close	4,890.00
Day's Range	4,877.50 - 4,981.00
52-Week Range	3,480.60 - 5,250.00
Beta	0.15
Analysts	Buy
Price Target	5,386.76 (+8.39%)
Earnings Date	Jul 30, 2026

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 18,258
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: TORNTPHARM

Financial Performance

In fiscal year 2026, Torrent Pharmaceuticals's revenue was 139.80 billion, an increase of 21.39% compared to the previous year's 115.16 billion. Earnings were 21.63 billion, an increase of 13.19%.

Analyst Summary

According to 29 analysts, the average rating for TORNTPHARM stock is "Buy." The 12-month stock price target is ₹5,387, which is an increase of 8.39% from the latest price.

Price Target

₹5,387

(8.39% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error